Jun 30, 2025 06:02AM OS Therapies (OSTX) Presents Statistically Significantly Positive 1-Year Event Free Survival

Jun 24, 2025 07:41AM OS Therapies (OSTX) Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2

Jun 10, 2025 07:40AM OS Therapies (OSTX) Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

Jun 6, 2025 07:31AM OS Therapies (OSTX) Submits Request for Regenerative Medicine Advanced Therapy Designation to FDA for OST-HER2

May 16, 2025 04:34PM OS Therapies Incorporated (OSTX) Reports Q1 Loss of $0.18

May 7, 2025 08:45AM OS Therapies (OSTX) Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Imm

Apr 22, 2025 07:41AM OS Therapies (OSTX) FDA Meeting Request Granted

Apr 22, 2025 07:34AM OS Therapies (OSTX) Halted, News Pending

Apr 9, 2025 07:40AM OS Therapies (OSTX) Completes Acquisition of Advaxis Immunotherapies Assets from Ayala Pharmaceuticals

Mar 31, 2025 07:40AM OS Therapies (OSTX) Provides Regulatory Update on OST-HER2

Feb 24, 2025 07:25AM OS Therapies (OSTX) Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

Feb 20, 2025 05:54AM OS Therapies (OSTX) Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2

Feb 14, 2025 07:36AM OS Therapies (OSTX) Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing

Feb 4, 2025 07:33AM OS Therapies (OSTX) Provides Corporate Update

Jan 15, 2025 07:45AM OS Therapies (OSTX) Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint

Dec 31, 2024 03:38PM OS Therapies (OSTX) Closes $6M Private Placement

Dec 26, 2024 10:03AM OS Therapies (OSTX) Partners with B2i Digital to Engage with Biotech Investors Online

Dec 24, 2024 09:32AM OS Therapies (OSTX) Prices 1.5M Unit Offering at $4/unit

Oct 28, 2024 04:44PM OS Therapies (OSTX) Appoints Avril McKean Dieser and Olivier R. Jarry to its Board

Sep 13, 2024 08:09AM OS Therapies (OSTX) Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

Sep 3, 2024 07:17AM EF Hutton Starts OS Therapies, Inc (OSTX) at Buy

Aug 29, 2024 07:53AM OS Therapies (OSTX) Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

Aug 22, 2024 01:01PM Brookline Capital Markets Starts OS Therapies, Inc (OSTX) at Buy

Aug 2, 2024 08:56AM OS Therapies (OSTX) Forms Osteosarcoma Patient Advocacy Advisory Board

Jul 24, 2024 10:50AM OS Therapies (OSTX) Reports Positive Safety Data from Phase 1 Clinical Trial of OST-HER2